Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440141 · ClinicalTrials.gov registry record · Phase 4
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00440141 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 40 participants.
The verdict
NCT00440141, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%
Interventions
- DRUG latanoprost 0.005% eye drops and brimonidine 0.1% eye drops
- DRUG latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440141
The ClinicalTrials.gov registry entry for NCT00440141 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which latanoprost 0.005% eye drops and brimonidine 0.1% eye drops is the first listed.
NCT00440141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00440141 about?
NCT00440141 is a clinical study titled "Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%". Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%
What is the current status of trial NCT00440141?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-07. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00440141?
The interventions under investigation include: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops (DRUG), latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops (DRUG).
Who is sponsoring clinical trial NCT00440141?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.